Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) General Information

Description

Rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1). CEACAM1 is a immune modulator blocking its interactions could strengthen immune cells' attack on cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Acquirer
Agenus
Primary Office
  • Fano
  • Italy
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)‘s full profile, request access.

Request a free trial

Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)‘s full profile, request access.

Request a free trial